Group items tagged

We have world's best neurologist neurosurgeons doctors team in India, they provide specialist consulting, diagnostic treatment services. Book an online appointment at your nearest Apollo Hospital all over across in India.

Apollo Hospitals has best team of urologist neurologist doctors and they provide best diagnostic & treatment services for various kidney & urological diseases

Looking for best Neurology and Neurosurgery treatment in India at affordable cost with easy hassle free visa processing support. Apollo Hospitals is one of the top hospitals who provide advanced and comprehensive care for patients at affordable costs.

The Global Pediatric Neurology Summit in New York 2023 is the premier event for pediatric neurologists from around the world. Learn more about new research and treatments, and discover the latest advancements in pediatrics neurology. Register today to join us.

An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.

This event provides an excellent opportunity for companies and organizations to showcase their products, services, and expertise to an engaged audience of pediatric neurologists and healthcare professionals.